# EDGAR Filing Document

**Accession Number:** 0001042074
**File Stem:** 0001193125-23-068543
**Filing Date:** 2023-3
**Character Count:** 5628
**Document Hash:** 5249dc8b228569dfbf92b0f2dc925ef0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-068543.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0001193125-23-068543

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230310

**ITEM INFORMATION**: Regulation FD Disclosure

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CymaBay Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001042074
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 943103561
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36500
- **FILM NUMBER:** 23725850

**BUSINESS ADDRESS:**
- **STREET 1:** 7575 GATEWAY BOULEVARD
- **STREET 2:** SUITE 110
- **CITY:** NEWARK
- **STATE:** CA
- **ZIP:** 94560
- **BUSINESS PHONE:** 510-293-8800

**MAIL ADDRESS:**
- **STREET 1:** 7575 GATEWAY BOULEVARD
- **STREET 2:** SUITE 110
- **CITY:** NEWARK
- **STATE:** CA
- **ZIP:** 94560

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** METABOLEX, INC.
- **DATE OF NAME CHANGE:** 20090721

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** METABOLEX INC
- **DATE OF NAME CHANGE:** 19970710

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, DC 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### PURSUANT TO SECTION 13 OR 15(d)

#### OF THE SECURITIES EXCHANGE ACT OF 1934

#### Date of Report (Date of earliest event reported): March 10, 2023

------

## CymaBay Therapeutics, Inc.

#### (Exact name of Registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36500** | **94-3103561** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission<br>File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

#### 7575 Gateway Blvd., Suite 110

#### Newark, CA 94560

#### (Address of principal executive offices)
(510) 293-8800

#### (Registrant's telephone number, including area code)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>symbol(s)** | **Name of each exchange<br>on which registered** |
| Common stock, $0.0001 par value per share | CBAY | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure.**  |

---

On March 10, 2023, Silicon Valley Bank (SVB) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (FDIC) as receiver.

SVB was the commercial bank and investment portfolio manager of CymaBay Therapeutics, Inc. CymaBay's investment portfolio (which was managed by SVB) is held at a third-party custodian for the benefit of CymaBay. As of March 13, 2023, CymaBay had depository accounts at SVB in which it held approximately $6.3 million, which represented less than 3% of its cash, cash equivalents and investments. These depository accounts were used by CymaBay to fund short-term working capital.

According to a joint statement by the Department of the Treasury, Federal Reserve and FDIC dated March 12, 2023, depositors will have access to all of their SVB deposits starting Monday, March 13, 2023.

*Forward-Looking Statements* 

This Current Report on Form 8-K contains "forward-looking" statements, which include, but are not limited to, the availability and timing of access to funds from depository accounts at SVB and CymaBay's ability to recover its cash on deposit at SVB. Actual results may differ from these expectations for a number of reasons, including, but not limited to, SVB's failure just occurred and regulatory authorities may take actions in response to the failure of SVB that CymaBay does not expect. All information provided in this Current Report on Form 8-K is as of March 13, 2023, and the Company undertakes no duty to update this information unless required by law.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| CymaBay Therapeutics, Inc. | CymaBay Therapeutics, Inc. |
| By: | /s/ Sujal Shah |
| Name: | Sujal Shah |
| Title: | Chief Executive Officer |

---

Dated: March 13, 2023